Description of Medical ServiceAn application was received for public funding through the Medicare Benefits Schedule (MBS) for a type of genetic testing. The test, called EndoPredict, is claimed to help determine the risk of a patient getting breast cancer again after they have had surgery.
Description of Medical ConditionPatients with ER positive and HER2 negative breast cancer following surgery.
Currently, combining information from clinical assessments and pathology test results helps doctors calculate whether a patient has a low, intermediate or high risk of breast cancer returning after surgery. This helps the patient decide, with their treating clinicians, whether to have chemotherapy in addition to their hormone therapy. The applicant claims that this decision is most difficult for patients whose existing information shows they have an intermediate risk of the cancer returning and that the EndoPredict genetic test can then provide valuable extra information to help this group of patients.
Reason for ApplicationNew MBS item
Medical Service TypeInvestigative
Previous Application NumberNot Applicable
PICO ConfirmationFinal Protocol (PDF 2940 KB)
Final Protocol (Word 245 KB)
Public Summary DocumentPublic Summary Document (PDF 576 KB)
Public Summary Document (Word 205 KB)